12 - Hot issues in Enterococcus faecalis bacteremia/endocarditis (IE)

Thursday, September 30, 2021

11:00 AM - 12:15 PM EDT

Moderator(s)

Jose M Miro, MD PhD

Dr.
Infectious Diseases Service
Hospital Clinic of Barelona
Barcelona, Catalonia, Spain

Abbvie (Individual(s) Involved: Self): Consultant; Angelini (Individual(s) Involved: Self): Consultant; Contrafect (Individual(s) Involved: Self): Consultant; Cubist (Individual(s) Involved: Self): Consultant; GENENTECH (Individual(s) Involved: Self): Consultant; Gilead (Individual(s) Involved: Self): Consultant
Pierre Tattevin, MD PhD

Head
ID unit, Rennes Univ. Hosp., France

ADVANZ PHARMA (Individual(s) Involved: Self): Consultant; EUMEDICA (Individual(s) Involved: Self): Consultant; GILEAD (Individual(s) Involved: Self): Consultant; PFIZER (Individual(s) Involved: Self): Consultant

Speaker(s)

JP

Juan Pericàs, MD, MPH, PhD

Senior Clinician and Investigator
Hospital Clínic de Barcelona & Vall d'Hebron University Hospital
Barcelona, Catalonia, Spain

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Emanuele Durante Mangoni, MD,, PhD

Associate professor of Internal Medicine
University of Campania 'Luigi Vanvitelli' - Monaldi Hospital
Napoli, Campania, Italy

Advanz pharma (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Angelini (Individual(s) Involved: Self): Board Member, Research Grant or Support, Speakers' bureau; Merck (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Nordic pharma (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Advisor or Review Panel member
AD

Anders Dahl, MD, PhD

Post doc
University Hospital of Copenhagen

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:

Jose M Miro, MD PhD: Abbvie (Individual(s) Involved: Self): Consultant; Angelini (Individual(s) Involved: Self): Consultant; Contrafect (Individual(s) Involved: Self): Consultant; Cubist (Individual(s) Involved: Self): Consultant; GENENTECH (Individual(s) Involved: Self): Consultant; Gilead (Individual(s) Involved: Self): Consultant

Pierre Tattevin, MD PhD: ADVANZ PHARMA (Individual(s) Involved: Self): Consultant; EUMEDICA (Individual(s) Involved: Self): Consultant; GILEAD (Individual(s) Involved: Self): Consultant; PFIZER (Individual(s) Involved: Self): Consultant

Juan M. Pericàs, MD, MPH, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Emanuele Durante Mangoni, MD,, PhD: Advanz pharma (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Angelini (Individual(s) Involved: Self): Board Member, Research Grant or Support, Speakers' bureau; Merck (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Nordic pharma (Individual(s) Involved: Self): Grant/Research Support, Speakers' bureau; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Advisor or Review Panel member

Anders Dahl, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

recognize the association between E. faecalis bacteremia/endocarditis and the presence of benign and malign colonic neoplasms
define the high risk of endocarditis in all patients with E. faecalis bacteremia and the indications of echocardiography
explain the best antimicrobial therapy for patients with E. faecalis bacteremia and endocarditis and the efficacy and safety of the two recommended antibiotic combinations (ampicillin plus either ceftriaxone or gentamicin)

Presentations:

Association of E. faecalis bacteremia/endocarditis and colonic neoplasms
Speaker: Juan M. Pericàs, MD, MPH, PhD – Hospital Clínic de Barcelona & Vall d'Hebron University Hospital
Enterococcus faecalis IE treatment
Speaker: Emanuele Durante Mangoni, MD,, PhD – University of Campania 'Luigi Vanvitelli' - Monaldi Hospital
Should positive blood cultures with E. faecalis be upgraded to count as major criteria of endocarditis?
Speaker: Anders Dahl, MD, PhD – University Hospital of Copenhagen